Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302163 | 1.00 | KDM4E (0.57) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL13390038 | 0.86 | MEN1 (0.52) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL14113535 | 0.86 | MEN1 (0.52) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL14113415 | 0.86 | HDAC3 (0.67) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL3303305 | 0.85 | CCNA2 (0.47) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL14113414 | 0.85 | CCNA2 (0.47) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL3303309 | 0.85 | CCNA2 (0.47) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL3302596 | 0.84 | CCR2 (0.50) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL14113450 | 0.84 | MEN1 (0.50) | KDM4EMEN1KMT2ANPC1MAPT | |
| SCHEMBL14113416 | 0.84 | MEN1 (0.50) | KDM4EMEN1KMT2ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | KDM4E 1803/4885MEN1 2505/4885KMT2A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.